The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Nov. 28, 8:59 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #29. Novartis CoStim Pharmaceuticals, Inc.

Acquirer: Novartis (NYSE:NVS)
Acquiree: CoStim Pharmaceuticals, Inc.
Details: MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. ("CoStim") has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

Novartis is a holding company. Through its subsidiaries, Co. is a multinational group of companies focusing on the research, development, manufacturing and marketing of a range of pharmaceuticals and generic medicines. Co. comprises two divisions: Innovative Medicines, which researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two global business units, Novartis Oncology and Novartis Pharmaceuticals; and Sandoz, which develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients, and has three franchises, Retail Generics, Anti-Infectives and Biopharmaceuticals.

Open the NVS Page at The Online Investor »

Company Name: 
Novartis AG Basel
Website: 
www.novartis.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding NVS: 
5
Total Market Value Held by ETFs: 
$130.98M
Total Market Capitalization: 
$245.88B
% of Market Cap. Held by ETFs: 
0.05%
 

Open the NVS Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree NVS Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.57 out of 4)
3rd percentile
(ranked lower than approx. 97% of all stocks covered)

Analysts' Target Price:
NVS Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 29 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.